Bee Allergy Shots (Venom Immunotherapy): 2.7% vs 39.8% Re-Sting Risk
Bee allergy shots — clinically called venom immunotherapy (VIT) — are a separate FDA-approved product class from environmental SCIT and the most effective form of allergen immunotherapy available. Cochrane Boyle 2012 (PMID 23076950): 2.7% systemic reaction rate in VIT-treated patients versus 39.8% in untreated controls on re-sting (RR 0.10). Five FDA-approved Hymenoptera venoms. Lifelong VIT required in mast-cell-disorder patients (Bonadonna 2013). VIT must be done in an allergist's office and is not available through at-home services.
7 peer-reviewed sources
Bee allergy shots are venom immunotherapy (VIT) — a separate FDA-approved product class from environmental SCIT. Cochrane 2012: 2.7% vs 39.8% systemic re-sting risk. VIT requires in-office administration and is not available through at-home allergy services.
The essentials
Bee allergy shots — venom immunotherapy (VIT) — are categorically distinct from environmental SCIT. They use purified Hymenoptera venom extracts, not the environmental allergen extracts used for pollen, dust mite, or pet dander. Hunt's landmark 1978 NEJM RCT (n=57) first proved that purified venom (not the whole-body extract used until then) was the effective component, documenting that whole-body extract injections were no more effective than placebo for preventing systemic sting reactions.
Curex's allergist review identifies when sting-reaction history and venom-specific IgE testing warrant referral to a board-certified allergist for venom immunotherapy — a distinct in-office product class separate from environmental SCIT and SLIT.
VIT efficacy is the most dramatic in the entire immunotherapy literature. Cochrane Boyle 2012 (Cochrane Database Syst Rev 2012;10:CD008838, PMID 23076950) documented subsequent systemic sting reactions in 3/113 (2.7%) VIT-treated patients versus 37/93 (39.8%) untreated controls — a relative risk of 0.10 (95% CI 0.03–0.28). Golden 2005 JACI reports overall VIT protection exceeding 95% (single vespid 85–90%, honey bee 75–85%). This is the strongest efficacy finding across all categories of allergen immunotherapy.
FDA-approved Hymenoptera venoms (CBER-licensed): honey bee (Apis mellifera), yellow jacket (Vespula spp.), paper wasp (Polistes spp.), yellow hornet (Dolichovespula arenaria), white-faced hornet (Dolichovespula maculata), and mixed vespid. VIT is indicated when a patient has: (1) a documented systemic sting reaction (generalized hives, angioedema, respiratory distress, hypotension — not just a large local skin reaction) AND (2) demonstrable venom-specific IgE on skin testing or serum sIgE. Per Cox 2011 PP3, children under 16 with cutaneous-only systemic reactions (generalized hives alone, without respiratory or cardiovascular involvement) typically do NOT require VIT — their sting-anaphylaxis risk is substantially lower than adults with the same reaction.
Maintenance dose is 100 µg of each relevant venom. Build-up to 100 µg is followed by maintenance injections every 4 weeks, extendable to every 6–8 weeks in stable patients, for a standard 3–5 year course. The 30-minute in-office observation period is mandatory at every VIT visit.
Lifelong VIT: in patients with systemic mastocytosis, clonal mast cell disease, or elevated baseline serum tryptase, VIT discontinuation carries unacceptably high re-sting risk. Bonadonna 2013 (J Allergy Clin Immunol 2013;132:125) documented the management of mastocytosis patients on VIT and established that lifelong continuation is appropriate when clonal mast cell disease is confirmed. US guidance now recommends baseline serum tryptase measurement in all adults presenting with a systemic sting reaction — an elevated baseline tryptase (above 11.4 ng/mL) warrants evaluation for clonal mast cell disease and likely lifetime VIT continuation. Hereditary alpha-tryptasemia (TPSAB1 duplication) is increasingly recognized as a co-factor for severe sting reactions.
VIT and epinephrine: all patients on VIT — even those successfully completing a full course — are advised to carry epinephrine auto-injectors (EpiPen, Auvi-Q, neffy nasal spray) because VIT reduces but does not eliminate sting-reaction risk. The 2.7% residual systemic-reaction rate in treated patients from the Cochrane meta-analysis confirms ongoing, albeit dramatically reduced, risk.
Africanized honeybee note: Apis mellifera scutellata (Africanized "killer bee") has the same Api m 1–5 venom allergens as European honeybees — the FDA-approved honey bee venom extract is cross-reactive and protective. Africanized bees deliver more venom per sting due to their swarm behavior, not because of qualitatively different venom proteins.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
VIT has the most dramatic efficacy of any immunotherapy. The Cochrane 2012 meta-analysis and landmark NEJM trials establish the quantitative case.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
VIT build-up carries a higher systemic-reaction rate than environmental SCIT build-up. All reactions must be managed in a clinical setting with epinephrine immediately available.
Frequently asked questions
What is the difference between bee allergy shots and environmental allergy shots?
Bee allergy shots — venom immunotherapy (VIT) — use purified Hymenoptera venom extracts (honey bee, yellow jacket, paper wasp, yellow hornet, white-faced hornet, mixed vespid) to prevent anaphylaxis on re-sting. Environmental SCIT uses allergen extracts from pollens, dust mites, animal dander, or molds to reduce allergic rhinitis and asthma symptoms. VIT and environmental SCIT are both subcutaneous immunotherapy but use entirely different extract products, have different indications, different evidence bases, and different administration protocols. Importantly, VIT requires in-office administration at an allergist's office and cannot be done through at-home alternatives.
Who needs bee venom immunotherapy?
Indication per Cox 2011 PP3: (1) a documented systemic sting reaction — meaning symptoms beyond the sting site, such as generalized hives, angioedema, respiratory distress, or hypotension; AND (2) demonstrable venom-specific IgE on skin testing or serum-specific IgE panel. Children under 16 who had a systemic reaction that was limited to generalized cutaneous symptoms (widespread hives only, no respiratory or cardiovascular involvement) typically do NOT require VIT — their risk of severe re-sting anaphylaxis is substantially lower than adults with the same presentation. Adults with cutaneous-only systemic reactions plus positive venom IgE are considered candidates.
How long do bee allergy shots take to work?
Protection from re-sting anaphylaxis begins once the 100 µg maintenance dose is reached — typically after 4–8 weeks of conventional build-up, or faster with rush or ultra-rush protocols. The level of protection is highest once maintenance is established. The standard VIT course is 3–5 years of maintenance injections. After completing the standard course, protection is durable in most patients — Golden 2000 NEJM documented long-term protection after discontinuing VIT. In mast-cell-disorder patients, VIT must continue lifelong (Bonadonna 2013 JACI 2013;132:125) because discontinuation carries unacceptably high risk.
Do bee allergy shots need to continue for life?
Most patients can discontinue VIT after 3–5 years with durable protection. However, for patients with systemic mastocytosis, clonal mast cell disease, or elevated baseline serum tryptase, VIT must be continued lifelong per current guidelines (Bonadonna P et al., J Allergy Clin Immunol 2013;132:125). Elevated baseline tryptase above 11.4 ng/mL warrants evaluation for clonal mast cell disease. Hereditary alpha-tryptasemia (TPSAB1 duplication) is increasingly recognized as an additional risk factor for severe sting reactions. For all VIT patients, carrying an epinephrine auto-injector after completing treatment is recommended given the residual risk.
Can you get bee allergy shots at home?
No. Venom immunotherapy (VIT) is a separate in-office product class that requires supervised administration at an allergist's office due to the elevated systemic-reaction risk during build-up (5–15% of patients) and the requirement for immediate epinephrine availability. At-home allergy services specialize in IgE testing and subcutaneous immunotherapy for environmental aeroallergens (pollen, dust mite, pet dander). If your history includes a systemic sting reaction, a board-certified allergist can identify the appropriate referral pathway for venom skin testing and VIT initiation. For environmental aeroallergens, Curex's At-Home Allergy Shot Kit delivers SCIT at $129/month — a personalized serum sterile-compounded to USP <797>, self-administered as one weekly shot at home, with the first dose supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on-hand; venom immunotherapy itself must remain at an allergist's office under the supervised injection protocol VIT requires.
What is the tryptase test and why is it important for bee sting allergy?
Baseline serum tryptase is a mast cell burden marker — levels above 11.4 ng/mL suggest elevated mast cell burden and warrant evaluation for clonal mast cell disease (systemic mastocytosis or monoclonal mast cell activation syndrome). Patients with elevated baseline tryptase who experience sting-triggered anaphylaxis have substantially higher re-sting risk than patients with normal tryptase. Current US guidance recommends baseline tryptase measurement in all adults presenting with a systemic sting reaction. If elevated, further evaluation for mastocytosis (bone marrow biopsy in selected cases) and lifelong VIT continuation is appropriate per Bonadonna 2013. Hereditary alpha-tryptasemia (TPSAB1 copy-number duplication, documented by Lyons 2016 Nat Genet) is a separate heritable condition associated with elevated baseline tryptase and severe mast cell reactions.
Are yellow jacket and wasp allergy shots the same as bee allergy shots?
VIT covers five FDA-approved Hymenoptera venoms: honey bee (Apis mellifera), yellow jacket (Vespula spp.), paper wasp (Polistes spp.), yellow hornet (Dolichovespula arenaria), and white-faced hornet (Dolichovespula maculata) — plus mixed vespid (combines the four vespid venoms). These are NOT cross-reactive with honey bee venom: a patient allergic to yellow jacket venom requires yellow jacket VIT, not honey bee. Most US stinging insect reactions are from yellow jackets, not honey bees. Identifying the culprit insect — by description of the sting event, nesting behavior, and appearance of the insect — is part of the allergist evaluation before venom skin testing.
Related Articles
Names of Allergy Shots for Adults | Curex Guide
The clinical name is SCIT. Extracts come from Greer, ALK-Abelló, or Stallergenes Greer. FDA-approved branded tablets: Grastek, Oralair, Ragwitek, Odactra.
Read morePollen Allergy Shot: 3-Way Triage Guide | Curex
Pollen allergy shot triage: depot steroid (discouraged), SLIT tablet, or SCIT. Curex at-home SCIT is category 3: shots weekly at home, $129/month.
Read moreAllergy Shots Pollen — Top-Funnel Guide | Curex
Allergy shots for pollen are SCIT targeting your specific IgE-sensitized pollens. Cochrane 51 RCTs: symptom SMD −0.73. 60–80 injections over 3–5 years. Full beginner guide.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreAllergy Shots for Environmental Allergies | Curex Guide
Environmental allergy SCIT: pollen, dust mite, cat, Alternaria. Cochrane 51 RCTs: SMD −0.73. 82% counties no allergist. At-home SCIT: $129/mo.
Read moreAllergy Shots for Dog Allergies | Curex Human SCIT Guide
Allergy shots for dog allergies treat HUMANS — not dogs. Dog SCIT evidence is 'poor and conflicting' (Smith 2016). 16.5% of dog-sensitized adults can skip shots entirely.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.